Q3:15 Health Care Deal Volume

by | Oct 26, 2015 9:15 am | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation

We’re just about to publish our third quarter results this week, but wanted to give you a sneak preview of how the third quarter stacks up against Q2:15 and the same quarter a year ago. Here’s the chart. SectorQ3:15 DealsQ2:15 DealsChangeQ3:14 DealsChange Services Behavioral Health Care10667%4150% Home Health & Hospice9650%15-40% Hospitals332438%1974% Labs, MRI & Dialysis16157%8100% Long-Term Care906538%856% Managed Care12850%5140% Physician Medical Groups1522-32%147% Rehabilitation7617%540% Other Services464015%3628% Services subtotal23819224%19125% Technology Biotechnology413421%27%52% eHealth3334-3%34-3% Medical Devices31297%2619% Pharmaceuticals423811%67-37%... Read More »

Q3:15 Health Care M&A, by Spending

by | Oct 19, 2015 8:56 am | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation

Last week we shared our data on health care M&A by sector in the third quarter of 2015. Here’s a look at the same sectors, by share of the dollars spent. If you’ve been following health care M&A at all, you won’t be surprised that the Managed Care sector (health insurers) accounts for about 50% of the $198 billion spent. That total, by the way, is also a new quarterly record. Look for The Health Care M&A Report, Third Quarter, for more in-depth analysis by sector. Read More »

Q3:15 Health Care M&A, By Sector

by | Oct 12, 2015 8:56 am | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Rehabilitation

Health care M&A in the third quarter was quite robust, with 385 transations reported across 13 sectors. That’s a new record for any third quarter, by the way. We’ll have the full break-out in The Health Care M&A Report, Third Quarter 2015, due to be published by the end of this month. In the meantime, here’s how the sectors fared in Q3:15. Read More »

Medtronic Acquires Lazarus Effect

by | Oct 5, 2015 8:58 am | Medical Devices

You have to admit, naming a company Lazarus Effect sets up some big expectations. Medtronic plc (NYSE: MDT) had that in mind, no doubt, when it paid $100 million for medical device maker Lazarus Effect in late September. The target’s lead product is the Lazarus Cover™, which complements Medtronic’s Solitaire™ stent retriever platform. The technology is designed to address clinical needs with a novel nitinol “mesh cover” that folds over a stent retriever device during clot retrieval and wraps the stent with the clot inside. Medtronic will report the Lazarus Effect product line as part of its Neurovascular division within the Restorative Therapies Group. Read More »

Teva Acquires Respiratory Care Software Platform

by | Sep 28, 2015 8:59 am | eHealth, Medical Devices, Pharmaceuticals

Teva Pharmaceutical (NYSE: TEVA) has had a busy year, making four divestitures and four acquisitions. Last week it tipped the balance in favor of acquisitions, with the purchase of privately held Gecko Health Solutions in Cambridge, Massachusetts. Gecko’s CareTRx™ platform is a novel cloud-based solution designed to simplify chronic respiratory disease management, connecting patients and caregivers through remote monitoring and real-time adherence tools. Teva hopes to apply the CareTRx technology to its pipeline and portfolio of respiratory products. Read More »

McKesson Buys Irish Drug Distribution Business

by | Sep 21, 2015 8:57 am | Medical Devices

McKesson Corporation (NYSE: MCK) got back into acquisition mode last week with its purchase of the pharmaceutical distribution division of UDG Healthcare plc for €408 million (US$463 million) in cash. Under terms of the agreement, McKesson will acquire United Drug Sangers in Northern Ireland and United Drug in the Republic of Ireland, as well as TCP, a leading home healthcare provider in the Republic of Ireland and MASTA, UDG’s travel healthcare business based in the United Kingdom. The deal boosts McKesson’s European drug distribution business, but not as much as its October 2013 deal for 75% of the German distributor Celesio AG, totaling $8.2 billion. In July, Celesio announced its UK... Read More »